Ocera Therapeutics

Ocera’s lead drug candidate OCR-002 is a novel ammonia scavenger which rapidly removes ammonia from the blood. Elevated ammonia is believed to be one of the primary causes of hepatic encephalopathy (HE). OCR-002 is the subject of STOP-HE, a Company-sponsored Phase 2b trial, and two investigator-sponsored Phase 2a trials. OCR-002 has received Orphan Drug designation in both the U.S. and Europe and has been granted Fast Track status by the U.S. Food and Drug Administration.

Company Growth (employees)
Type
Public
HQ
Palo Alto, US
Founded
2005
Size (employees)
20 (est)
Ocera Therapeutics was founded in 2005 and is headquartered in Palo Alto, US

Ocera Therapeutics Office Locations

Ocera Therapeutics has offices in Palo Alto and Durham
Palo Alto, US (HQ)
610 525 University Ave
Durham, US
300 5001 S Miami Blvd

Ocera Therapeutics Metrics

Ocera Therapeutics Financial Metrics

Market capitalization (28-Apr-2017)

$30 m

Closing share price (28-Apr-2017)

$1.3

Cash (31-Dec-2016)

$24.6 m
Ocera Therapeutics's current market capitalization is $30 m.
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$15.5 m$10.1 m$35.9 m$24.6 m

Accounts Receivable

$93 k$62 k$59 k

Inventories

$470 k$970 k$627 k$584 k

Current Assets

$49.3 m$48.3 m$44 m$28.9 m

PP&E

$59 k$61 k$94 k$64 k

Goodwill

$595 k$595 k$595 k$595 k

Total Assets

$51.8 m$53.1 m$44.7 m$29.6 m

Accounts Payable

$1.3 m$941 k$701 k$1.2 m

Total Debt

$19 m

Current Liabilities

$6.7 m$2.9 m$3.8 m$13.8 m

Additional Paid-in Capital

$126.6 m$155.1 m$162.8 m$174.1 m

Retained Earnings

($104.9 m)($131.4 m)($158.3 m)

Total Equity

$31.4 m$15.7 m

Debt to Equity Ratio

0.6 x

Debt to Assets Ratio

0.4 x

Financial Leverage

1.4 x1.9 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($17.5 m)($23.4 m)($26.5 m)($26.9 m)

Depreciation and Amortization

$295 k$164 k$171 k

Accounts Receivable

$45 k$31 k$3 k

Inventories

Accounts Payable

$14 k($341 k)($240 k)$514 k

Cash From Operating Activities

($12 m)($20.3 m)($20.6 m)($22.1 m)

Purchases of PP&E

($12 k)($38 k)($75 k)($14 k)

Cash From Investing Activities

($21.3 m)($8.9 m)$33.2 m$3.6 m

Cash From Financing Activities

$7.2 m

Interest Paid

$828 k

Ocera Therapeutics Market Value History

Ocera Therapeutics Online Presence

Ocera Therapeutics Company Life

You may also be interested in